Aleniglipron Pill Delivers 12.1% Weight Loss in 36 Weeks in Phase II Trial
Updated
Updated · ScienceDaily · Aug 10
Aleniglipron Pill Delivers 12.1% Weight Loss in 36 Weeks in Phase II Trial
3 articles · Updated · ScienceDaily · Aug 10
Summary
In 230 adults at 38 U.S. centers, aleniglipron cut body weight by 9.0% to 12.1% over 36 weeks, versus 0.5% with placebo in a randomized phase II trial.
The once-daily GLP-1 candidate is a small-molecule pill rather than an injectable peptide, allowing dosing with or without food and potentially easier large-scale manufacturing.
Gastrointestinal side effects were mostly mild to moderate and eased over time, while 10.4% of participants discontinued treatment and researchers reported no drug-induced liver injury.
The results, published in Nature Medicine, support a phase III trial as developers seek an oral obesity treatment that could broaden access beyond drugs such as Wegovy and Ozempic.
Could a simple daily pill without fasting rules finally dethrone blockbuster weight-loss injections like Wegovy and Ozempic?
With phase III trials launching now in 2026, will slower dose escalations unlock massive weight loss without the dreaded gastrointestinal side effects?
Aleniglipron and the Oral GLP-1 Revolution: Pivotal Phase 3 Data, 16%+ Weight Loss, and the Race to Transform Global Obesity Care by 2030
Overview
Aleniglipron, Structure Therapeutics’ once-daily oral GLP-1 receptor agonist, is advancing into Phase 3 trials after strong Phase 2 results and positive FDA feedback. By starting patients at a low 2.5 mg dose and gradually increasing, the drug shows improved tolerability and fewer side effects, making it easier for patients to stay on treatment. Oral GLP-1 therapies like aleniglipron are set to reshape obesity care by removing the need for injections and cold storage, lowering costs, and expanding access through primary care. This shift, combined with new insurance coverage and employer support, could make effective obesity treatment more affordable and widely available.